Immune response data from FLAMINGO-01 shows positive results in patients with HER2+ breast cancer, suggesting potential for ...

Greenwich LifeSciences (NASDAQ:GLSI) added ~23% in the premarket on Wednesday after the company posted preliminary immune ...

Greenwich LifeSciences, Inc. (Nasdaq: GLSI) (the "Company"), a clinical-stage biopharmaceutical company focused on its Phase ...

It involves approximately 500 patients with the HLA-A02 allele randomized to receive either GLSI-100 or a placebo, with an additional 250 patients of other HLA types receiving GLSI-100 in the open ...

Greenwich LifeSciences (GLSI), a clinical-stage biopharmaceutical company focused on its Phase III clinical trial, FLAMINGO-01, which is ...

Immune response data in both the HLA-A*02 treated and placebo arms and the third open label arm with all other HLA types (non- HLA-A*02), show that GLSI-100 is creating an immune response over ...

Citing early data from FLAMINGO-01, the Stafford, Texas-based biotech said there were immune responses in both HLA-A*02 patients and non-HLA-A*02 patients who were part of GLSI-100/placebo arms ...